Open AccessEfficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis
Author(s) -
Jonathan Edwards,
L Szczepański,
Jacek Szechiński,
Anna FilipowiczSosnowska,
Paul Emery,
David Close,
Randall M. Stevens,
Tim Shaw
Publication year - 2004
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa032534
Subject(s) - medicine , rituximab , rheumatoid arthritis , randomized controlled trial , b cell , oncology , immunology , antibody , lymphoma
An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind, controlled study.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom